Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
5-Amino-1MQ was developed as a pharmacological tool to inhibit NNMT activity, and preclinical studies have demonstrated that oral administration of 5-Amino-1MQ to obese rodents produces dose-dependent reductions in body weight and fat mass, improvements in glucose metabolism and insulin sensitivity, and increases in energy expenditure - remarkably, these effects occur without changes in food intake, indicating that 5-Amino-1MQ works through metabolic enhancement and increased caloric burn rather than appetite suppression
Examples of GLP-1s include semaglutide (Wegovy), and liraglutide (Saxenda)
-20C, 1 month (sealed storage, away from moisture)
Its important to know that compounded GLP-1 medications arent FDA-approved, and the FDA hasnt reviewed them for safety, quality, or how well they work
This information is for research and educational use only
With the right guidance, the benefits often outweigh the risks
